AR042103A1 - Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion - Google Patents
Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacionInfo
- Publication number
- AR042103A1 AR042103A1 ARP030104295A ARP030104295A AR042103A1 AR 042103 A1 AR042103 A1 AR 042103A1 AR P030104295 A ARP030104295 A AR P030104295A AR P030104295 A ARP030104295 A AR P030104295A AR 042103 A1 AR042103 A1 AR 042103A1
- Authority
- AR
- Argentina
- Prior art keywords
- human growth
- growth hormone
- human
- hgh
- peg conjugate
- Prior art date
Links
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 5
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 5
- 239000000854 Human Growth Hormone Substances 0.000 abstract 5
- 229920001223 polyethylene glycol Polymers 0.000 abstract 4
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010012559 Developmental delay Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 108700031632 somatrem Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Una hormona de crecimiento humana (hGH) modificada químicamente preparada uniendo un resto de polietilenglicol-butiraldehído a la fenilalanina N-terminal de la proteína. La proteína modificada químicamente puede tener una actividad hGH de mucha mayor duración que la hGH no modificada, posibilitando una dosis reducida y oportunidades de cambio de régimen. Reivindicación 1: Un conjugado de hormona de crecimiento humana-PEG caracterizado porque tiene la estructura de fórmula (1) o fórmula (2) en la que n es un número entero entre 1 y 10; m es un número entero entre 1 a y 10; R es una hormona de crecimiento humana u hormona de crecimiento humana metionilo. Reivindicación 8: Una composición caracterizada porque comprende el conjugado de hormona de crecimiento humano-PEG de las reivindicaciones 1, 2, 3, 4, 5, 6 o 7 y al menos un vehículo farmacéuticamente aceptable. Reivindicación 9: Un procedimiento de tratamiento de un paciente que tiene un trastorno de crecimiento o desarrollo, caracterizado porque comprende administrar a dicho paciente una cantidad terapéuticamente eficaz del conjugado hormona de crecimiento humana-PEG de las reivindicaciones 1, 2, ,3, 4, 5, 6, o 7.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42782302P | 2002-11-20 | 2002-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042103A1 true AR042103A1 (es) | 2005-06-08 |
Family
ID=32825103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104295A AR042103A1 (es) | 2002-11-20 | 2003-11-20 | Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040127417A1 (es) |
AR (1) | AR042103A1 (es) |
GT (1) | GT200300250A (es) |
NL (3) | NL1024831C2 (es) |
PA (1) | PA8588901A1 (es) |
PE (1) | PE20040797A1 (es) |
SV (1) | SV2004001674A (es) |
TW (1) | TWI281864B (es) |
UY (1) | UY28085A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
US7157546B2 (en) | 2002-09-09 | 2007-01-02 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
ES2343518T3 (es) * | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | Polipeptidos interferon alfa modificados resistentes a proteasas. |
US20040136952A1 (en) * | 2002-12-26 | 2004-07-15 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
EA008866B1 (ru) * | 2002-12-26 | 2007-08-31 | Маунтин Вью Фамэсьютикэлс, Инк. | ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
JP2007522198A (ja) * | 2004-02-09 | 2007-08-09 | ファルマシア コーポレーション | 化学修飾されたヒト成長ホルモン受容体アンタゴニスト結合体 |
EP1805216A2 (en) * | 2004-10-18 | 2007-07-11 | Novo Nordisk A/S | Growth hormone conjugates |
JP2008517033A (ja) * | 2004-10-18 | 2008-05-22 | ノボ ノルディスク アクティーゼルスカブ | オキシム、チアゾリジン、ジチアン、ジチオランまたはヒドラゾンが連結した成長ホルモンの類似体の作製方法 |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
WO2006102659A2 (en) * | 2005-03-23 | 2006-09-28 | Nektar Therapeutics Al, Corporation | CONJUGATES OF AN hGH MOIETY AND A POLYMER |
EP1928906A2 (en) * | 2005-08-30 | 2008-06-11 | Novo Nordisk Health Care AG | Liquid formulations of pegylated growth hormone |
WO2007097934A2 (en) * | 2006-02-17 | 2007-08-30 | Elusys Therapeutics, Inc. | Methods and compositions for using erythrocytes as carriers for delivery of drugs |
KR20100014215A (ko) * | 2006-07-07 | 2010-02-10 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 신규 단백질 접합체 및 그것의 제조 방법 |
US20090252703A1 (en) * | 2006-10-19 | 2009-10-08 | Gegg Jr Colin V | Use of alcohol co-solvents to improve pegylation reaction yields |
EP2157432A1 (en) * | 2008-08-15 | 2010-02-24 | Qiagen GmbH | Method for analysing a complex sample by mass spectrometry |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
EP3355384A1 (en) * | 2017-01-31 | 2018-08-01 | Universite De Liege | Flexible thin-films for battery electrodes |
CN114539384B (zh) * | 2020-11-19 | 2024-09-06 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化长效生长激素及其制备方法和医药应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4342832A (en) * | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
US5618697A (en) * | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
JP2989002B2 (ja) * | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
JP3051145B2 (ja) * | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
JP3628333B2 (ja) * | 1995-09-21 | 2005-03-09 | ジェネンテック インコーポレーテッド | ヒト成長ホルモン変異体 |
KR100731826B1 (ko) * | 1999-01-14 | 2007-06-22 | 볼더 바이오테크놀로지 인코퍼레이티드 | 유리 시스테인 잔기를 함유하는 단백질의 제조 방법 |
SE9904502D0 (sv) * | 1999-12-09 | 1999-12-09 | Pharmacia & Upjohn Ab | Production of peptides |
-
2003
- 2003-11-19 PA PA20038588901A patent/PA8588901A1/es unknown
- 2003-11-19 TW TW092132405A patent/TWI281864B/zh not_active IP Right Cessation
- 2003-11-20 SV SV2003001674A patent/SV2004001674A/es not_active Application Discontinuation
- 2003-11-20 PE PE2003001178A patent/PE20040797A1/es not_active Application Discontinuation
- 2003-11-20 NL NL1024831A patent/NL1024831C2/nl not_active IP Right Cessation
- 2003-11-20 AR ARP030104295A patent/AR042103A1/es unknown
- 2003-11-20 UY UY28085A patent/UY28085A1/es not_active Application Discontinuation
- 2003-11-20 US US10/718,340 patent/US20040127417A1/en not_active Abandoned
- 2003-11-20 GT GT200300250A patent/GT200300250A/es unknown
-
2005
- 2005-04-21 NL NL1028837A patent/NL1028837C2/nl not_active IP Right Cessation
-
2006
- 2006-08-07 NL NL1032282A patent/NL1032282C2/nl not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NL1028837A1 (nl) | 2005-08-30 |
TW200418878A (en) | 2004-10-01 |
NL1032282A1 (nl) | 2006-11-07 |
GT200300250A (es) | 2004-08-18 |
TWI281864B (en) | 2007-06-01 |
US20040127417A1 (en) | 2004-07-01 |
UY28085A1 (es) | 2004-07-30 |
SV2004001674A (es) | 2004-05-17 |
NL1032282C2 (nl) | 2007-03-09 |
PE20040797A1 (es) | 2004-12-10 |
NL1024831A1 (nl) | 2004-05-26 |
PA8588901A1 (es) | 2005-02-04 |
NL1028837C2 (nl) | 2006-08-14 |
NL1024831C2 (nl) | 2005-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR042103A1 (es) | Conjugados de hormona de crecimiento humana pegilados n- terminales y proceso para su preparacion | |
AR017780A1 (es) | Conjugado del factor de liberacion de hormona de crecimiento-polietilenenglicol (hgrf-peg) y metodo para la preparacion en sitio-especifico del mismo. | |
CY1106723T1 (el) | Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων | |
JPH05505808A (ja) | 創傷の治癒を促進するためへの銅(2)含有化合物の使用 | |
HRP20020787B1 (en) | Method of treatment using ligand-immunogen conjugates | |
CY1119369T1 (el) | Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α | |
GEP20063860B (en) | Chemically-modified human growth hormone conjugates | |
PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
KR101831465B1 (ko) | 단백질 결합 프로드러그를 갖는 약물 조합 | |
ES2227527T3 (es) | Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada. | |
AR006598A1 (es) | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" | |
CY1106283T1 (el) | Κινολινυλ-πυρρολοπυραζολες | |
BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
MX9700552A (es) | Conjugados de vitamina b12 y proteinas. | |
CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
EA200200194A1 (ru) | Антагонисты хемокинного рецептора и способы их применения | |
NO20024646L (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
DE69914084D1 (de) | Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen | |
DE60137146D1 (de) | Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten | |
DE69924304D1 (de) | N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin | |
AR002018A1 (es) | Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
ATE179618T1 (de) | Pharmazeutische zusammensetzungen, enthaltende polymerverbundene anthracycline-glykosiden, und verfahren zu deren herstellung | |
PE20000131A1 (es) | Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden | |
ATE549036T1 (de) | Thymosin-alpha-1-peptid/polymer-konjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |